Side effects during long-term treatment with depot antipsychotic medication

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Long-term antipsychotic medication for schizophrenia is associated with adverse effects.
• Weight gain and tardive dyskinesia are common concerns in schizophrenia treatment.
• Extrapyramidal side effects and depression can persist during maintenance therapy.

Purpose of the Study:

• To compare the long-term efficacy and safety of haloperidol decanoate and fluphenazine decanoate in schizophrenia patients.
• To assess the incidence of weight changes, extrapyramidal side effects, and depression.
• To provide evidence on the relative benefits of these two antipsychotic treatments.

Main Methods:

• A large, multicenter, double-blind, comparative trial involving 181 schizophrenia patients.
• One-year treatment duration with regular patient assessments.
• Utilized scales including Krawiecka, Montgomery-Asberg (schizophrenia/depression), Simpson-Angus (parkinsonism), AIMS (tardive dyskinesia), and akathisia scale.
• Patient weight was monitored throughout the study.

Main Results:

• Further evidence on weight changes during long-term antipsychotic therapy was gathered.
• The study provided data on the occurrence of extrapyramidal side effects and depression.
• Comparative benefits of haloperidol decanoate versus fluphenazine decanoate were analyzed.

Conclusions:

• Long-term antipsychotic treatment necessitates careful monitoring for side effects.
• Haloperidol decanoate and fluphenazine decanoate present distinct side effect profiles.
• Understanding these profiles aids in optimizing schizophrenia management.